Clinical trial
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
NCT01057810 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT01057810 |
|---|---|
| Title | Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer |
| Official title | Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Ipilimumab, Placebo |
| Enrollment | 837 |
| Start date | Jul 1, 2010 |
| Primary completion | Apr 1, 2015 |
| Completion | Jul 1, 2015 |
| First posted | Jan 27, 2010 |
| Last update posted | Aug 18, 2016 |
| Countries | Argentina, Australia, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary and 12 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: